斯蒂芬·达令：进博会为我们提供了一个直接与消费者互动的机会。我们尝试将品牌的理念讲给消费 者，也向消费者学习该怎样去生产、推出商品，这是一个螺旋式上升的过程。展会结束后，我们会系统 讨论意见与反馈，更好地将公司的产品推广出去。 斯蒂芬·达令 小小伞品牌创始人 本届进博会，170家企业和27家机构第八年参展，成为展会的"全勤生"。同时，本届进博会参展企业较 上届新增600多家，其中不乏第一次参展的"新面孔"。记者邀请到连续8年参展的德国生命科学企业拜耳 和首次参展的新西兰儿童营养品牌小小伞相关负责人，请他们分享对于进博会以及中国市场的看法与期 待。 记者：作为全球首个以进口为主题的国家级展会，进博会常办常新、越办越好，您如何看待进博会这一 平台？ 张蕾：进博会给企业提供了将展品变为商品、从展商变为投资商的机会。我刚开始参展的时候，跨国企 业更多是把全球的创新成果带到中国。随着进博会的举办，跨国企业有更多机会了解中国市场、接触中 国的消费者和客户，和中国合作伙伴建立更紧密的联系，实现共创共享。 斯蒂芬·达令：我们很早就知道进博会这一平台，考虑到今年公司业务足够成熟，我们才选择主动参 加。通过进博会，我们找到了不少 ...

Core Insights - Bayer's Health Consumer Division showcased five "global first" innovative products at the 8th China International Import Expo, emphasizing its commitment to providing comprehensive health solutions throughout consumers' life cycles [1][6][11] - The company views the expo as a vital platform for connecting the Chinese market with global resources, reflecting confidence in China's supply chain and innovation potential [4][23] Product Innovations - Bayer's new products address specific health management needs, including a B5 cream for diaper rash, a nasal spray for allergic rhinitis, a lactulose solution for constipation, high-purity EPA fish oil for cardiovascular health, and a calcium supplement for children [9][10][19] - The B5 cream is designed for sensitive skin, providing 16 hours of protection, while the nasal spray is recommended for children and adults [9][10] Strategic Collaborations - Bayer is deepening local collaborations through its China Innovation Cooperation Center (CCIP), focusing on "产学研" (industry-academia-research) partnerships to enhance health accessibility [13][17] - Strategic agreements were signed with local partners, including Shanghai Tianwu Technology for AI applications in health management and Shandong Jingwei Pharmaceutical for self-care solutions [15][17] Health Education Initiatives - Bayer hosted various health education activities at the expo, including forums on AI in health management and lectures on allergy prevention and digestive health [19][21] - The company aims to enhance public understanding of health issues through these initiatives, addressing consumer pain points in allergy treatment and digestive health [21][23] Global Innovation Strategy - Bayer positions the expo as a strategic anchor for its operations in China, linking local insights with global research and development [23] - The company is expanding its product offerings from local markets to international ones, exemplified by its collaboration with Xianle Health to reach broader markets [23]

Core Insights - Bayer views the China International Import Expo (CIIE) as a crucial platform for integrating into China's development and seizing opportunities, particularly in the women's health sector [1][11] - Bayer has signed a strategic cooperation memorandum with JD Health to enhance ecosystem development in chronic diseases, women's health, and oncology, aiming for resource sharing and complementary advantages [1][8] Group 1: CIIE Participation and Achievements - Bayer has showcased over 50 first-time products at CIIE and has successfully incubated multiple "CIIE babies," resulting in nearly 40 significant contracts [3] - In the upcoming 2024 CIIE, Bayer will launch the "Women's Health Ecosystem," integrating medical, research, public welfare, and digital platforms for comprehensive women's health management [3] Group 2: Women's Health Product Matrix - Bayer has introduced a comprehensive product matrix addressing women's health across different life stages, including contraceptives and treatments for endometrial diseases [6][7] - The company has presented seven innovative products at CIIE, including oral contraceptives and a non-hormonal treatment for menopausal symptoms, emphasizing a holistic approach to women's health [6][7] Group 3: Collaboration with JD Health - The partnership with JD Health aims to enhance women's health literacy and create a professional content library, leveraging digital platforms for broader reach [10] - Bayer and JD Health will explore innovative cooperation models to establish a digital ecosystem in women's health, enhancing accessibility and efficiency of health services [10][11]

在AI技术重塑全球产业格局的当下，健康消费领域正迎来前所未有的创新机遇。作为全球领先的健康 消费品企业，拜耳正积极构建AI驱动的创新生态。 11月7日，拜耳健康消费品依托第八届中国国际进口博览会（以下简称"进博会"）这一全球性开放平 台，成功举办"未来已来：AI赋能自我健康管理"主题活动，深度解码AI技术在医药产业与健康消费领域 的落地实践、核心瓶颈与未来路径，为行业创新发展注入强劲动能。 作为扎根中国140余年的跨国企业，拜耳的中国布局从处方药领域，拓展至OTC（非处方药）、健康消 费品等多个板块，已成为中国健康产业不可或缺的重要参与者。如今，拜耳已连续八年参展进博会，进 博会早已成为其兑现创新承诺、链接全球资源与本土需求的核心枢纽。 依托进博会的资源整合与联动效能，拜耳正进一步加码AI在健康领域的落地，一方面推动B端（面向企 业）研发生产的技术革新，另一方面也借助数字化合作打通C端（面向消费者）消费场景的需求响应， 让AI从技术概念融入健康管理全链条，为消费者提供更精准高效的智能化解决方案。 从泡沫突围到落地深耕，技术与生态双轮驱动 在AI技术席卷全球的浪潮中，医药产业作为高投入、长周期、高风险的典型领域 ...

Core Viewpoint - The article emphasizes the strategic opportunities in China's pharmaceutical and healthcare sector, particularly in the context of the "14th Five-Year Plan" and the upcoming "15th Five-Year Plan," highlighting the importance of health in national development and the need for enhanced public health initiatives [1]. Policy and Strategic Initiatives - The "15th Five-Year Plan" proposes a health-first development strategy, aiming to increase the average life expectancy in China from 79 years in 2024 to around 80 years [1]. - The 8th China International Import Expo (CIIE) showcased cutting-edge technologies and innovative products in the healthcare sector, indicating a strong response from the industry to policy initiatives [1]. Chronic Disease Management - Cardiovascular diseases remain a significant health threat in China, with over 330 million patients, and low awareness and treatment rates for blood lipid management [3]. - Collaborative efforts, such as the "Super Consultation" event by Tencent News and Novartis, aim to address public misconceptions about LDL-C and improve cardiovascular disease management [3]. Innovations in Disease Prevention - GSK is focusing on product innovation and health education to promote the prevention of diseases closely related to chronic conditions, such as shingles, which poses increased risks for patients with cardiovascular diseases [4][5]. - Bayer introduced a new product for chronic constipation management, addressing a prevalent health issue among adults in China [5]. Retail Health Services - The retail sector is crucial in connecting healthcare services with public health, with initiatives to extend health services from hospitals to homes [7]. - Novo Nordisk and the China Pharmaceutical Commerce Association launched a health management standard for obesity in retail pharmacies, aiming to enhance patient support [7][9]. AI in Healthcare - AI technology is increasingly integrated into healthcare, enhancing clinical diagnosis and patient management, as demonstrated by various companies at the CIIE [13]. - The launch of AI-driven platforms, such as Boston Scientific's medical knowledge graph, aims to improve clinical education and decision-making [13][14]. Ecosystem Collaboration - The CIIE serves as a platform for collaboration among healthcare companies, fostering partnerships that enhance innovation and market access [18]. - Companies like Merck and Medtronic are focusing on local partnerships to accelerate the introduction of innovative products in China [19][20]. Conclusion - The healthcare sector in China is undergoing significant transformation driven by policy support, technological advancements, and collaborative efforts among industry players, aiming to improve public health outcomes and enhance the overall healthcare ecosystem [1][18].

Core Viewpoint - Bayer's launch of Aflibercept 8mg during the China International Import Expo aims to address the increasing burden of neovascular age-related macular degeneration (nAMD) and improve patient compliance and quality of life [1][2]. Group 1: Product Launch and Approval - Aflibercept 8mg was approved by the National Medical Products Administration in May 2023 for the treatment of nAMD [1]. - The product features a longer treatment interval, which is expected to enhance patient adherence to treatment [1]. Group 2: Disease Background and Treatment Gaps - nAMD is characterized by abnormal growth and leakage of new blood vessels in the macula, leading to irreversible vision loss in the elderly [1]. - Current treatment methods, primarily anti-VEGF injections, show significant gaps in disease control and require frequent administration, which affects long-term treatment adherence [1]. Group 3: Product Advantages - Aflibercept is a fully humanized fusion protein that offers broader inhibition of the VEGF family compared to monoclonal antibodies [2]. - The higher concentration of Aflibercept 8mg allows for a greater number of molecules to be injected at once, resulting in more effective and durable VEGF inhibition [2]. - The upgrade to Aflibercept 8mg provides stronger early efficacy and more durable disease control, offering clinicians and patients more flexible treatment options [2].

Core Insights - Bayer's Eylea® 8mg (Aflibercept 8mg) was launched during the China International Import Expo, approved for treating neovascular age-related macular degeneration (nAMD) in May 2023, offering a more effective and longer-interval treatment option for patients [1][2] Group 1: Product Overview - Eylea® 8mg provides a treatment regimen starting with monthly injections for the first three months, which can then be extended to every four months based on clinical assessment [1] - The product aims to enhance treatment adherence and quality of life for nAMD patients, addressing unmet medical needs [1][2] Group 2: Clinical Validation - The clinical value of Eylea® 8mg was validated in the pivotal Phase III PULSAR study, showing comparable vision improvement with longer injection intervals compared to the 2mg dosage [2] - Eylea® 8mg demonstrated a faster and higher rate of fluid resolution during the loading phase, addressing the need for reduced injection frequency while maintaining vision benefits [2] Group 3: Market Context - nAMD is a progressive eye disease leading to irreversible vision loss, with the number of affected individuals in China projected to rise from 4.5 million in 2020 to 8.8 million by 2050 [1] - Without timely intervention, approximately 75.7% of nAMD patients may progress to legal blindness within three years, highlighting the urgent need for effective treatment solutions [1]

Core Insights - Bayer's Eylea® 8mg (Aflibercept 8mg) was launched during the China International Import Expo, approved for treating neovascular age-related macular degeneration (nAMD) in May 2023, offering a more effective and longer treatment interval for patients [1][2] - The product aims to enhance patient compliance and quality of life by reducing the frequency of injections from monthly to potentially every four months based on clinical assessments [1][2] Group 1 - Eylea® 8mg provides a significant upgrade in dosage and formulation, demonstrating strong early efficacy and prolonged disease control, which alleviates the burden of frequent hospital visits for patients [1][2] - The prevalence of nAMD in China is projected to rise from 4.5 million in 2020 to 8.8 million by 2050, with a high risk of progression to legal blindness if not treated promptly [1] - Bayer emphasizes a patient-centered approach, continuously addressing unmet medical needs in the field of ophthalmology [1][2] Group 2 - Current clinical guidelines recommend anti-VEGF injections as the first-line treatment for nAMD, yet there are significant gaps in disease control and treatment adherence due to short drug efficacy and high injection frequency [2] - The clinical value of Eylea® 8mg has been validated in the pivotal Phase III PULSAR study, showing comparable vision improvement with fewer injections compared to the 2mg dosage [2] - Eylea® 8mg has already commenced patient injections in several provinces in China, with expectations for broader patient access to this innovative treatment [2]

Core Insights - Bayer's Eylea 8mg (Aflibercept 8mg) was launched during the 8th China International Import Expo, approved by the National Medical Products Administration for the treatment of neovascular age-related macular degeneration (nAMD) [1] Industry Overview - The burden of nAMD is increasing, with the number of patients in China expected to rise from 4.5 million in 2020 to 8.8 million by 2050 [1] - Without timely intervention, approximately 75.7% of patients may progress to legal blindness within three years, significantly impacting personal quality of life and placing economic pressure on society [1] Product Launch - Eylea 8mg has already completed the first batch of patient injections in multiple provinces and cities across China [1]

Core Insights - Bayer Pharmaceuticals and Beijing Humanoid Robotics Innovation Center signed a cooperation agreement during the 8th China International Import Expo to promote the development of humanoid robots and embodied intelligence technology in solid drug manufacturing, packaging, quality control, warehousing, and logistics [1] Group 1: Collaboration Details - The partnership aims to evaluate the use cases of emerging robots in pharmaceutical production processes, exploring the stability, compatibility, and value creation potential of new robotic technologies in pharmaceutical operations [1] - Both parties will collaborate in the "robotics + high-end manufacturing" sector, focusing on material transportation, quality monitoring, and product packaging to assess the feasibility of integrating embodied intelligent robot products and services into Bayer's production lines [1] Group 2: Industry Context - Embodied intelligence is characterized by high-quality, high-performance intelligent systems capable of rapid and precise responses in dynamic environments, with humanoid robots serving as a key carrier of this technology [1] - The concept of embodied intelligence is gaining traction, transitioning from theoretical frameworks to practical applications, as highlighted in the recent government work report that emphasizes the establishment of a growth mechanism for future industries, including biomanufacturing, quantum technology, embodied intelligence, and 6G [1]